Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone.
about
Neurokinin-1 receptor antagonists for prevention of chemotherapy-related nausea and vomiting in adultsChemotherapy-and cancer-related nausea and vomitingNeurokinin-1 receptor antagonists for prevention of chemotherapy-related nausea and vomiting in adultsManagement of Chemotherapy Induced Nausea and Vomiting in Patients on Multiday Cisplatin Based Combination ChemotherapyDrug-drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical dataFosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomitingSafety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program.Risk Factors for Early-Onset Peripheral Neuropathy Caused by Vincristine in Patients With a First Administration of R-CHOP or R-CHOP-Like ChemotherapyEffects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients.Update and new trends in antiemetic therapy: the continuing need for novel therapies.Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition.The NK₁ receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma.Rolapitant for the treatment of chemotherapy-induced nausea and vomiting: a review of the clinical evidence.Betamethasone in pregnancy: influence of maternal body weight and multiple gestation on pharmacokinetics.Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients.Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting.Comparative evaluation of triplet antiemetic schedule versus doublet antiemetic schedule in chemotherapy-induced emesis in head and neck cancer patients.Antiemetic therapy in cancer: an update.Update on anti-emetics for chemotherapy-induced emesis.Aprepitant (EMEND): the role of substance P in nausea and vomiting.An approach to evaluating drug-nutrient interactions.Clinical practice guidelines on antiemetics in oncology.Emerging drugs for chemotherapy-induced emesis.The neurokinin1 receptor antagonist aprepitant as an antiemetic for moderately emetogenic chemotherapy.Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary.Recent advances in pharmacotherapy of chemotherapy-induced nausea and vomiting.A systematic review on drug interactions in oncology.Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trialPrevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitantDrug interactions in childhood cancer.Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant.Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients.Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant.Tachykinin receptor antagonists in clinical trials.Combination of Aprepitant, Azasetron, and Dexamethasone as Antiemetic Prophylaxis in Women with Gynecologic Cancers Receiving Paclitaxel/Carboplatin Therapy.Aprepitant: drug-drug interactions in perspective.Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting.Use of high-dose cisplatin with aprepitant in an outpatient setting.Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting.
P2860
Q24200792-D6538A67-C18B-4A84-8899-0F6DBCD9A59AQ24644831-C67D1FBC-D04C-4E0D-93B3-731A03E364ECQ26472106-0EB6C77C-B6CB-465E-ADD6-03E770353660Q26783177-6258C5B5-9CF0-42CA-A1F7-0A3265084547Q28084970-B6DAEF9D-46D8-443E-8E41-4B8FA81E1855Q28258863-84CC2944-524E-40F4-BDF8-2899F19D0E7CQ31061449-0B3111A6-7601-49D5-A338-1DEDD5CF582FQ33688318-E62DF67D-A5EF-4E5C-93AD-90F47D10A51EQ34046633-F41EE876-BB0C-42D3-9036-F7F5587D2B24Q34143667-CCECF0A0-2C57-4A6C-AFA1-7C0F0865B1A3Q34278794-5B6B8F5D-0CD5-4893-8382-8D2298CF4EF7Q34457463-F4EE2E0C-0FB1-4216-8BEB-B0E1F77020DBQ34512212-B1DD418B-B9F8-419A-BAA8-7532174256B3Q35077796-021DFEDE-0D23-40F1-AEE2-28CC5936390FQ35182204-6A324679-E1B9-4A4D-9869-0BC63448816BQ35962019-57B30568-1D07-4306-8AE7-E3CFCC57B6B9Q36093627-C1D630D4-BA19-4F98-ADA6-B910F7CCD7D9Q36222061-5DFA6E39-F3FB-404F-8FA6-9A5E8DAA9BE0Q36263659-55FE201B-A556-4F0B-882D-B3D61A137B74Q36284018-4EC99739-7433-4520-9634-322876414814Q36320632-5E808E56-7C51-4D08-A198-08F1F03E2CB9Q36334870-A771A97C-6357-4067-8FF3-4CEA08F25BEDQ36407422-6C013729-FEC0-4611-BB59-35A426E4914EQ36548740-8DB9F367-9E0A-4504-B54E-AB922E9B02F7Q36564254-CFE846CA-D273-42BF-BA7C-C803A8D51642Q36575446-BE46D701-0BB3-4732-B7AA-67FC4FFA21A8Q36659821-524F6824-2BF7-4F89-B7EE-42D83B40870BQ36702393-15075E03-7BC8-4D74-95D9-F7D47DA437ABQ36823546-8017794D-D087-4A85-9355-B8A01A2D2E62Q36898141-02581323-63D9-4127-B31D-1815359F10E3Q36920404-BCC2D03C-D5B6-409C-8FA4-D019F731BEFEQ37316977-1C2213C7-0FCA-4DAF-BE00-40778B5F4300Q37355479-FE6871F9-8F2B-4121-87C3-D1EDBA6166E1Q37636064-8F99ACAB-DB35-4CBF-B501-D8FC26B0A932Q37638682-B1745E7B-B831-47F3-96D7-F0EE48053907Q37661865-D5835F45-94FF-45CA-B592-085C24C6C343Q37757799-A1FCF078-58A1-4F53-A5AB-825CD8E35F3BQ37854702-F1819D2A-01FA-4970-93C3-D7906346844EQ37924902-9376FAF4-7C2F-4BB6-A44E-F34A10597700Q37982438-BAC099D9-3F25-462A-8480-3342432988F2
P2860
Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Effects of the neurokinin1 rec ...... hasone and methylprednisolone.
@en
Effects of the neurokinin1 rec ...... hasone and methylprednisolone.
@nl
type
label
Effects of the neurokinin1 rec ...... hasone and methylprednisolone.
@en
Effects of the neurokinin1 rec ...... hasone and methylprednisolone.
@nl
prefLabel
Effects of the neurokinin1 rec ...... hasone and methylprednisolone.
@en
Effects of the neurokinin1 rec ...... hasone and methylprednisolone.
@nl
P2093
P1476
Effects of the neurokinin1 rec ...... hasone and methylprednisolone.
@en
P2093
Anup K Majumdar
Christopher R Lines
Cynthia Gargano
D Ronald Goldwater
Deborah L Panebianco
Jacqueline B McCrea
Keith M Gottesdiener
Kevin J Petty
M Gail Murphy
Marian Iwamoto
P356
10.1016/S0009-9236(03)00066-3
P407
P577
2003-07-01T00:00:00Z